Summary of Study ST002481

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001603. The data can be accessed directly via it's Project DOI: 10.21228/M8H131 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Study ID	ST002481
Study Title	Urolithin A (UroA) acts at CYP1A1/1B1 substrates leading to enhanced aryl hydrocarbon receptor (AHR) activity in vivo
Study Summary	Many AHR ligands are CYP1A1/1B1 substrates, which can result in the rapid clearance within the intestinal tract and other tissues, limiting both the level and duration of AHR activation. This leads to the hypothesis that there are dietary constituents capable of inhibiting CYP1A1/1B1 increasing the half-live of potent AHR ligands. To test this hypothesis, we examined the ability of urolithin A (UroA) to act at CYP1A1/1B1 substrates leading to enhanced AHR activity in vivo.
Institute	Pennsylvania State University
Last Name	DONG
First Name	FANGCONG
Address	309 Life Sciences Building, State college, PA, 16802, USA
Email	fxd93@psu.edu
Phone	8146990203
Submit Date	2023-02-16
Raw Data Available	Yes
Raw Data File Type(s)	mzML
Analysis Type Detail	LC-MS
Release Date	2023-03-02
Release Version	1

Select appropriate tab below to view additional metadata details:

Project:

Project ID:	PR001603
Project DOI:	doi: 10.21228/M8H131
Project Title:	Urolithin A (UroA) acts at CYP1A1/1B1 substrates leading to enhanced aryl hydrocarbon receptor (AHR) activity in vivo
Project Summary:	Many AHR ligands are CYP1A1/1B1 substrates, which can result in the rapid clearance within the intestinal tract and other tissues, limiting both the level and duration of AHR activation. This leads to the hypothesis that there are dietary constituents capable of inhibiting CYP1A1/1B1 increasing the half-live of potent AHR ligands. To test this hypothesis, we examined the ability of urolithin A (UroA) to act at CYP1A1/1B1 substrates leading to enhanced AHR activity in vivo.
Institute:	Pennsylvania State University
Last Name:	FANGCONG
First Name:	DONG
Address:	309 Life Sciences Building, State college, PA, 16802, USA
Email:	fxd93@psu.edu
Phone:	8146990203

Subject:

Subject ID:	SU002571
Subject Type:	Cultured cells
Subject Species:	Mus musculus
Taxonomy ID:	10090

Factors:

Subject type: Cultured cells; Subject species: Mus musculus (Factor headings shown in green)

mb_sample_id	local_sample_id	Time (min)
SA248214	4_UroA_0_2	0
SA248215	4_UroA_0_3	0
SA248216	3_ICZ_0_1	0
SA248217	2_luciferin CEE_0_2	0
SA248218	3_ICZ_0_3	0
SA248219	4_UroA_0_1	0
SA248220	1_UroA_0_1	0
SA248221	2_luciferin CEE_0_1	0
SA248222	3_ICZ_0_2	0
SA248223	2_luciferin CEE_0_3	0
SA248224	1_UroA_0_3	0
SA248225	1_UroA_0_2	0
SA248226	1_UroA_10_3	10
SA248227	1_UroA_10_2	10
SA248228	1_UroA_10_1	10
SA248253	5_Purified diet_2	120
SA248254	5_Purified diet_3	120
SA248255	5_Purified diet_1	120
SA248256	5_Purified diet_UroA_2	120
SA248257	5_Purified diet_UroA_3	120
SA248258	5_Purified diet_UroA_1	120
SA248259	3_ICZ_120_1	120
SA248260	3_ICZ_UroA_120_1	120
SA248261	3_ICZ_120_3	120
SA248262	3_ICZ_120_2	120
SA248263	3_ICZ_UroA_120_2	120
SA248264	3_ICZ_UroA_120_3	120
SA248265	3_ICZ_UroA_without NADPH_120_2	120
SA248266	3_ICZ_UroA_without NADPH_120_1	120
SA248267	3_ICZ_UroA_without NADPH_120_3	120
SA248229	1_UroA_20_1	20
SA248230	1_UroA_20_3	20
SA248231	1_UroA_20_2	20
SA248232	1_UroA_40_3	40
SA248233	1_UroA_40_2	40
SA248234	1_UroA_40_1	40
SA248235	4_UroA_90_2	90
SA248236	4_UroA_ICZ_without NADPH_90_1	90
SA248237	4_UroA_ICZ_without NADPH_90_3	90
SA248238	4_UroA_ICZ_90_3	90
SA248239	4_UroA_ICZ_90_2	90
SA248240	4_UroA_90_3	90
SA248241	4_UroA_ICZ_90_1	90
SA248242	4_UroA_90_1	90
SA248243	2_luciferin CEE_without NADPH_90_2	90
SA248244	2_luciferin CEE_ICZ_90_2	90
SA248245	2_luciferin CEE_ICZ_90_3	90
SA248246	2_luciferin CEE_ICZ_90_1	90
SA248247	2_luciferin CEE_90_3	90
SA248248	2_luciferin CEE_90_1	90
SA248249	2_luciferin CEE_90_2	90
SA248250	2_luciferin CEE_without NADPH_90_1	90
SA248251	4_UroA_ICZ_without NADPH_90_2	90
SA248252	2_luciferin CEE_without NADPH_90_3	90

Showing results 1 to 54 of 54

Showing results 1 to 54 of 54

Collection:

Collection ID:	CO002564
Collection Summary:	40 µg microsomes isolated from Hepa 1 cells treated with 5 nM TCDD for 24 h, or lung microsomes (100 µg) from mice on the semi-purified diet, were incubated with various compounds and incubation times as indicated. The reactions were carried out at 37°C in an incubator in the presence of NADPH regeneration system and terminated by addition of 800 µL ice cold 100% methanol (v/v) containing 1 µM chlorpropamide as internal standard.
Sample Type:	Hepa 1 cells

Treatment:

Treatment ID:	TR002583
Treatment Summary:	Then mixtures were kept in -20°C for 30 mins followed by centrifugation at 12,000 × g for 20 min at 4°C. The supernatants were dried in a under vacuum and reconstituted in 60 μL 50% methanol (v/v). After centrifugation, supernatants were transferred to autosampler vials for LC-MS/MS analysis.

Sample Preparation:

Sampleprep ID:	SP002577
Sampleprep Summary:	40 µg microsomes isolated from Hepa 1 cells treated with 5 nM TCDD for 24 h, or lung microsomes (100 µg) from mice on the semi-purified diet, were incubated with various compounds and incubation times as indicated. The reactions were carried out at 37°C in an incubator in the presence of NADPH regeneration system and terminated by addition of 800 µL ice cold 100% methanol (v/v) containing 1 µM chlorpropamide as internal standard. Then mixtures were kept in -20°C for 30 mins followed by centrifugation at 12,000 × g for 20 min at 4°C. The supernatants were dried in a under vacuum and reconstituted in 60 μL 50% methanol (v/v). After centrifugation, supernatants were transferred to autosampler vials for LC-MS/MS analysis.

Sampleprep ID:

SP002577

Sampleprep Summary:

40 µg microsomes isolated from Hepa 1 cells treated with 5 nM TCDD for 24 h, or lung microsomes (100 µg) from mice on the semi-purified diet, were incubated with various compounds and incubation times as indicated. The reactions were carried out at 37°C in an incubator in the presence of NADPH regeneration system and terminated by addition of 800 µL ice cold 100% methanol (v/v) containing 1 µM chlorpropamide as internal standard. Then mixtures were kept in -20°C for 30 mins followed by centrifugation at 12,000 × g for 20 min at 4°C. The supernatants were dried in a under vacuum and reconstituted in 60 μL 50% methanol (v/v). After centrifugation, supernatants were transferred to autosampler vials for LC-MS/MS analysis.

Combined analysis:

Analysis ID	AN004051
Analysis type	MS
Chromatography type	Reversed phase
Chromatography system	Shimadzu 20AD
Column	BEH C18 column (2.1 × 100 mm × 1.7 µm particle size)
MS Type	ESI
MS instrument type	QTOF
MS instrument name	ABI Sciex 5600 TripleTOF
Ion Mode	UNSPECIFIED
Units	1

Chromatography:

Chromatography ID:	CH002998
Instrument Name:	Shimadzu 20AD
Column Name:	BEH C18 column (2.1 × 100 mm × 1.7 µm particle size)
Column Temperature:	55
Flow Gradient:	The initial condition were 97% A and 3 % B, increasing to 45% B at 10 min, 75% B at 12 min where it was held at 75% B until 17.5 min before returning to the initial conditions.
Flow Rate:	0.25 mL/min
Solvent A:	100% wate; 0.1% formic acid
Solvent B:	100% acetonitrile; 0.1% formic acid
Chromatography Type:	Reversed phase

MS:

MS ID:	MS003798
Analysis ID:	AN004051
Instrument Name:	ABI Sciex 5600 TripleTOF
Instrument Type:	QTOF
MS Type:	ESI
MS Comments:	The capillary voltage was set at 5.5 kV in positive ion mode with a declustering potential of 80 V. The mass spectrometer was operated with a 100 ms TOF scan from 50 to 500 m/z, and 16 MS/MS product ion scans (100 ms) per duty cycle using a collision energy of 50 V with a 20 V spread.
Ion Mode:	UNSPECIFIED